Remove 2027 Remove Communication Remove Pharmaceutical Companies
article thumbnail

COPD market to reach $30.8 billion in 7MM by 2033: GlobalData

Express Pharma

Other KOLs have communicated that Dupixent is to dominate the biologics market after receiving both EMA and FDA approval, filling a gap in the COPD market. The changes made by GOLD have communicated that ICS/LABA fixed-dose combinations should not be used, which has been reflected in the COPD report, highlighting a 1.4 billion by 2033.”

article thumbnail

Potential and Challenges of the APAC Pharmaceutical Industry

Viseven

from 2022 to 2027. Specifically, she engaged with several important stakeholders and received valuable information about future sales and marketing strategies, decision-making vision, and innovation trends among Chinese pharmaceutical companies. This role is significant because the pharma market in APAC is increasing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

High biologics demand spurs need for greater contract manufacturing

Pharmaceutical Technology

As a result, some pharmaceutical companies are turning to third parties. GlobalData forecasts Biologics to significantly overtake sales of small molecules by $120 billion by 2027. Moreover, skilled manpower is required to run these facilities. Please check your email to download the Whitepaper.

article thumbnail

Pliant snags $287.5 million in oversubscribed public offering amid market uncertainty

Pharmaceutical Technology

A Pliant spokesperson said, “This successful transaction, along with existing cash, cash equivalents, loan agreement and short-term investments, provides for operations to be funded to mid-2027, a year past the expected IPF Phase 2b clinical trial readout.” The company said a Phase IIb trial initiation should be expected in mid-2023.